Advertiment
Traslational Cancer Drugs Pharma, S.L., (“TCD”) has announced that the FDA has approved its Investigational New Drug (IND) application to begin a Phase I clinical study with its Choline Kinase Alpha inhibitor, TCD-717, for the treatment of solid tumors.
The clinical development plan for TCD-717 is designed to expedite the drug candidate through the clinical development path. The Phase I trial will be conducted in two medical centers in the US and will assess the safety and pharmacokinetic profile of TCD-717 administered intravenously over four hours. In preclinical testing, TCD-717 has demonstrated marked anti-cancer activity in xenograft models of lung cancer, colon cancer, breast cancer and bladder cancer.
“TCD-717 shows tremendous potential for the treatment of a wide range of cancers,” said Ran Vigdor, CEO of TCD, “The compound has also demonstrated promising synergistic effects with standard chemotherapy in different indications suggesting it could have significant benefit in combination with standard treatments. We believe TCD-717 is an exciting and worthy first candidate generated by the Company”.
TCD-717 is a novel, first-in-class, precisely-targeted small-molecule inhibitor of Choline Kinase Alpha (ChoK?). ChoK? is an enzyme centrally involved in regulating the production of phosphatidylcholine (a key building block in the formation of the cell’s membrane). TCD has demonstrated that ChoK? is crucial to a number of processes involved in cancer including independent cell proliferation, evasion of apoptosis, increased cell motility and metastasis. Moreover, the Company has shown that inhibition of ChoK? while merely temporarily arresting the cell cycle in normal cells, results in a toxic effect leading to cell death in cancer cells.
With ChoK? and TCD-717, TCD is employing a personalized and targeted treatment strategy – the patient’s eligibility for the treatment is determined by qRT-PCR analysis of tumor samples for ChoK? overexpression. Once eligibility is established, TCD-717 would then be administered resulting in the targeted destruction of tumor cells whilst leaving normal cells unharmed.
Source:
Traslational Cancer Drugs Pharma S.L
Related Search
new INDs breast cancer 2012,
TCD Announces First Patient Treated In Its TCD-717 Phase I,
TCD-717,
Leave a Reply
Suggested Posts
Potential Strategy Aims To Stimulate The Immune System To Defeat Cancers Traslatio al Ca cer Drugs Pharma, S.L., (“TCD”) has a ou ced that the FDA has approved its I vestigatio al New Drug (IND) applicatio to begi a Phase I cli ical study with its Choli e Ki ase Alpha i hibitor, TCD-717, for the treatme t of solid tumors. The cli ical developme t pla for TCD-717 is desig ed to expedite the drug ca didate through the cli ical [...]. Posted September 29th, 2010 | 2:13 am
Smoking May Be Discouraged By Population-Specific Community-Based Cancer Screening Traslatio al Ca cer Drugs Pharma, S.L., (“TCD”) has a ou ced that the FDA has approved its I vestigatio al New Drug (IND) applicatio to begi a Phase I cli ical study with its Choli e Ki ase Alpha i hibitor, TCD-717, for the treatme t of solid tumors. The cli ical developme t pla for TCD-717 is desig ed to expedite the drug ca didate through the cli ical [...]. Posted September 29th, 2010 | 2:13 am
Breakthrough In Loading Gold Nanorods Into Cells Could Lead To New Cancer Treatment Traslatio al Ca cer Drugs Pharma, S.L., (“TCD”) has a ou ced that the FDA has approved its I vestigatio al New Drug (IND) applicatio to begi a Phase I cli ical study with its Choli e Ki ase Alpha i hibitor, TCD-717, for the treatme t of solid tumors. The cli ical developme t pla for TCD-717 is desig ed to expedite the drug ca didate through the cli ical [...]. Posted September 29th, 2010 | 2:13 am
Scientists Discover Post-Production Addition To Most Proteins Can Serve As A Key To Mediate Protein Interactions, Which Are At The Foundation Of Life Traslatio al Ca cer Drugs Pharma, S.L., (“TCD”) has a ou ced that the FDA has approved its I vestigatio al New Drug (IND) applicatio to begi a Phase I cli ical study with its Choli e Ki ase Alpha i hibitor, TCD-717, for the treatme t of solid tumors. The cli ical developme t pla for TCD-717 is desig ed to expedite the drug ca didate through the cli ical [...]. Posted September 29th, 2010 | 2:13 am
Risk of second cancer in cancer survivors mainly confined to the same cancer type as the first Traslatio al Ca cer Drugs Pharma, S.L., (“TCD”) has a ou ced that the FDA has approved its I vestigatio al New Drug (IND) applicatio to begi a Phase I cli ical study with its Choli e Ki ase Alpha i hibitor, TCD-717, for the treatme t of solid tumors. The cli ical developme t pla for TCD-717 is desig ed to expedite the drug ca didate through the cli ical [...]. Posted September 29th, 2010 | 2:13 am